Johnson & Johnson (JNJ)
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Precio Actual
Capitalización
Desviación
Y/Y Growth
EBIT Margin
ROIC
PEG Ratio
ROE
3Y EPS Growth
Dividend Yield
Net Debt / EBITDA
Proyecciones CAGR
Proyecciones de tasa de crecimiento anual compuesta basadas en diferentes modelos de valoración. CAGR EV/FCF es la métrica principal.
Múltiplos de Valoración
Múltiplos de valoración utilizados para las estimaciones de CAGR y precios objetivo.
Gráfico de Evolución del Precio
Precios Objetivo FCF
Precios futuros estimados de la acción basados en proyecciones de flujo de caja libre.
Calculadora de Sensibilidad
Compara el CAGR de tu valoración con el que resultaría al aplicar diferentes múltiplos (LTM y Fair P/E).
Notas
Rendimiento Histórico vs. Índices
Rendimiento anual (YTD) de la acción comparado con índices y materias primas de referencia.
| Año | Rendimiento JNJ | Rendimiento Bitcoin | Rendimiento vs. Bitcoin | Rendimiento Gold | Rendimiento vs. Gold | Rendimiento Bono USA 7-10y | Rendimiento vs. Bono USA 7-10y | Rendimiento Bono USA 1-3y | Rendimiento vs. Bono USA 1-3y | Rendimiento Bono USA 20+y | Rendimiento vs. Bono USA 20+y | Rendimiento Dow Jones | Rendimiento vs. Dow Jones | Rendimiento S&P 500 | Rendimiento vs. S&P 500 | Rendimiento NASDAQ 100 | Rendimiento vs. NASDAQ 100 | Rendimiento MSCI World | Rendimiento vs. MSCI World | Rendimiento Russell 2000 | Rendimiento vs. Russell 2000 | Rendimiento STOXX Europe 600 | Rendimiento vs. STOXX Europe 600 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025 YTD en Vivo | 40.21% | -1.40% | +41.61% | 57.46% | -17.25% | 4.29% | +35.92% | 0.99% | +39.22% | 0.69% | +39.52% | 13.12% | +27.09% | 16.85% | +23.36% | 22.29% | +17.92% | 20.22% | +19.99% | 12.99% | +27.22% | 13.34% | +26.87% |
2024 | -9.60% | 110.77% | -120.37% | 26.96% | -36.55% | -3.73% | -5.87% | 0.05% | -9.64% | -11.17% | +1.57% | 12.80% | -22.40% | 24.01% | -33.61% | 30.78% | -40.37% | 17.88% | -27.48% | 10.80% | -20.39% | 5.50% | -15.10% |
2023 | -12.04% | 153.66% | -165.70% | 11.76% | -23.79% | -0.15% | -11.89% | 0.98% | -13.02% | -2.54% | -9.49% | 13.74% | -25.78% | 24.73% | -36.77% | 44.52% | -56.56% | 21.92% | -33.96% | 15.78% | -27.82% | 11.67% | -23.71% |
2022 | 2.98% | -65.23% | +68.20% | 0.78% | +2.20% | -15.93% | +18.91% | -5.00% | +7.98% | -31.00% | +33.98% | -9.40% | +12.38% | -19.95% | +22.93% | -33.89% | +36.87% | -19.70% | +22.68% | -22.50% | +25.48% | -13.29% | +16.26% |
2021 | 9.31% | 60.33% | -51.02% | -6.24% | +15.55% | -4.15% | +13.46% | -0.98% | +10.29% | -5.94% | +15.24% | 20.23% | -10.92% | 28.79% | -19.48% | 23.20% | -13.89% | 21.22% | -11.91% | 15.39% | -6.08% | 21.66% | -12.35% |
2020 | 7.82% | 301.93% | -294.11% | 23.90% | -16.09% | 8.33% | -0.51% | 2.02% | +5.80% | 15.12% | -7.31% | 6.02% | +1.80% | 15.29% | -7.48% | 41.75% | -33.93% | 12.94% | -5.12% | 18.48% | -10.67% | -4.64% | +12.46% |
2019 | 14.18% | 88.85% | -74.67% | 17.78% | -3.59% | 5.55% | +8.63% | 1.20% | +12.99% | 10.91% | +3.27% | 21.91% | -7.73% | 28.34% | -14.15% | 34.60% | -20.42% | 25.23% | -11.04% | 23.05% | -8.87% | 23.42% | -9.23% |
2018 | -7.31% | -71.79% | +64.48% | -3.12% | -4.20% | -0.97% | -6.34% | -0.24% | -7.07% | -3.17% | -4.14% | -6.03% | -1.28% | -7.01% | -0.30% | -5.30% | -2.01% | -11.16% | +3.85% | -13.00% | +5.69% | -13.42% | +6.11% |
2017 | 20.61% | 1,184.56% | -1,163.95% | 11.93% | +8.68% | 0.76% | +19.85% | -0.63% | +21.24% | 6.03% | +14.58% | 24.33% | -3.72% | 18.42% | +2.20% | 27.16% | -6.54% | 19.45% | +1.16% | 12.45% | +8.16% | 7.16% | +13.46% |
2016 | 14.66% | 109.91% | -95.25% | 6.53% | +8.13% | -1.15% | +15.81% | -0.02% | +14.68% | -1.91% | +16.57% | 15.24% | -0.58% | 11.24% | +3.42% | 9.79% | +4.87% | 6.53% | +8.13% | 22.42% | -7.76% | 1.33% | +13.33% |
| Media | 8.08% | 187.16% | -179.08% | 14.77% | -6.69% | -0.71% | +8.80% | -0.16% | +8.25% | -2.30% | +10.38% | 11.20% | -3.11% | 14.07% | -5.99% | 19.49% | -11.41% | 11.45% | -3.37% | 9.59% | -1.50% | 5.27% | +2.81% |
Historial de Valoración
Historial de cambios significativos en los factores de valoración y precios objetivo a lo largo del tiempo. Los valores resaltados indican un cambio respecto a la valoración anterior.
Fecha de Valoración | Y/Y Growth | EBIT Margin | Net Debt/EBITDA | P/E | EV/FCF | EV/EBITDA | EV/EBIT | Objetivo 2025 | Objetivo 2026 | Objetivo 2027 | Objetivo 2028 | Objetivo 2029 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/5/2025 | 5% | 33.6% | 0.4x | 16x(41x) | 18x | 13x | 14x | $200.77 | $223.20 | $247.61 | $269.99 | $294.39 |
| 9/24/2025 | 4.5% | 33.4% | 0.4x | 17x(18x) | 18x | 13x | 15x | $200.50 | $221.28 | $243.58 | $264.57 | $287.38 |
Historial de Dividendos
Evolución de los dividendos por acción pagados durante los últimos 10 años.Dividend Achiever - 10+ años de crecimiento continuo
| Año | Dividendo por Acción | Crecimiento |
|---|---|---|
| 2025 Actual | $4.91 | +4.47% |
| 2024 | $4.70 | +5.62% |
| 2023 | $4.45 | +6.21% |
| 2022 | $4.19 | +5.28% |
| 2021 | $3.98 | +6.13% |
| 2020 | $3.75 | +5.93% |
| 2019 | $3.54 | +6.63% |
| 2018 | $3.32 | +5.40% |
| 2017 | $3.15 | +6.78% |
| 2016 | $2.95 | - |
Análisis de Outperformance
Rendimiento histórico vs índices principales y métricas de consistencia
Outperformance Promedio vs Índices
Rendimiento promedio comparado con los principales índices del mercado
Evolución del Rendimiento Año a Año
Rendimiento histórico con marcadores de mejores y peores años
Consistencia de Rendimiento
Porcentaje de años con rendimientos positivos
JNJ shows moderate consistency with positive returns in 70% of years.